Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1959 2
1960 1
1961 2
1962 2
1963 3
1964 2
1965 2
1967 1
1968 2
1971 2
1978 2
1981 1
1983 1
1984 1
1985 2
1986 3
1987 7
1988 3
1989 4
1990 7
1991 4
1992 4
1993 7
1994 4
1995 6
1996 7
1997 17
1998 7
1999 5
2000 17
2001 16
2002 21
2003 20
2004 14
2005 12
2006 5
2007 28
2008 28
2009 38
2010 29
2011 31
2012 29
2013 19
2014 22
2015 39
2016 19
2017 40
2018 34
2019 37
2020 39
2021 38
2022 44
2023 38
2024 46
2025 40
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

765 results

Results by year

Filters applied: . Clear all
Page 1
Australasian hidradenitis suppurativa management guidelines.
Frew J, Smith A, Penas PF, Ellis E, Foley P, Rubel D, McMeniman E, Marshman G, Saunders H, Veysey E, Nicolopolous J, Spelman L, Gebauer K. Frew J, et al. Among authors: foley p. Australas J Dermatol. 2025 Mar;66(2):75-89. doi: 10.1111/ajd.14388. Epub 2024 Nov 22. Australas J Dermatol. 2025. PMID: 39578415 Free PMC article.
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
Weidinger S, Blauvelt A, Papp KA, Reich A, Lee CH, Worm M, Lynde C, Kataoka Y, Foley P, Wei X, Wong W, Solente AC, Weber C, Adelman S, Davey S, Hurbin F, Rynkiewicz N, Yen K, O'Malley JT, Bernigaud C. Weidinger S, et al. Among authors: foley p. J Allergy Clin Immunol. 2025 Apr;155(4):1264-1275. doi: 10.1016/j.jaci.2024.10.031. Epub 2024 Nov 8. J Allergy Clin Immunol. 2025. PMID: 39522654 Free article. Clinical Trial.
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy.
Silverberg JI, Bieber T, Paller AS, Beck L, Kamata M, Puig L, Wiseman M, Ezzedine K, Irvine AD, Foley P, Del Rosso J, Gold LS, Johansson E, Dossenbach M, Gallo G, Akmaz B, Casillas M, Karlsson A, Curteis T, Chovatiya R. Silverberg JI, et al. Among authors: foley p. Dermatol Ther (Heidelb). 2025 Mar;15(3):615-633. doi: 10.1007/s13555-025-01357-7. Epub 2025 Feb 14. Dermatol Ther (Heidelb). 2025. PMID: 39953372 Free PMC article. Review.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Gordon KB, et al. Among authors: foley p. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. Lancet. 2018. PMID: 30097359 Clinical Trial.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Strober B, et al. Among authors: foley p. J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14. J Am Acad Dermatol. 2023. PMID: 36115523 Free article. Clinical Trial.
Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis.
Choon SE, Foley PA, Asawanonda P, Fujita H, Jo SJ, Shi YL, Theng C, Affandi AM, Bang CH, Frez ML, Huei HY, Le Huu D, Kim TG, Morita A, Oon HH, Fernández-Peñas P, Rajatanavin N, Robinson S, Selvarajah L, Tsai TF. Choon SE, et al. Among authors: foley pa. J Dermatol. 2024 Dec;51(12):1579-1595. doi: 10.1111/1346-8138.17471. Epub 2024 Oct 10. J Dermatol. 2024. PMID: 39390737 Free PMC article.
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Kalra PR, et al. Among authors: foley pwx. Lancet. 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5. Lancet. 2022. PMID: 36347265 Free article. Clinical Trial.
Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
Cleland JGF, Kalra PA, Pellicori P, Graham FJ, Foley PWX, Squire IB, Cowburn PJ, Seed A, Clark AL, Szwejkowski B, Banerjee P, Cooke J, Francis M, Clifford P, Wong A, Petrie C, McMurray JJV, Thomson EA, Wetherall K, Robertson M, Ford I, Kalra PR; IRONMAN Study Group. Cleland JGF, et al. Among authors: foley pwx. Eur Heart J. 2024 Apr 21;45(16):1410-1426. doi: 10.1093/eurheartj/ehae086. Eur Heart J. 2024. PMID: 38446126 Free PMC article. Clinical Trial.
NeurHistAlert 28.
Stahnisch FW, Foley P. Stahnisch FW, et al. Among authors: foley p. J Hist Neurosci. 2025 Oct-Dec;34(4):697-712. doi: 10.1080/0964704X.2025.2575182. Epub 2025 Nov 10. J Hist Neurosci. 2025. PMID: 41208523 Review. No abstract available.
765 results